MRNA vs ORLY

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 13, 2026

MRNA

39.1
AI Score
VS
ORLY Wins

ORLY

48.6
AI Score

Investment Advisor Scores

MRNA

39score
Recommendation
SELL

ORLY

49score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MRNA ORLY Winner
Revenue 534.00M 9.45B ORLY
Net Income -2.13B 1.32B ORLY
Net Margin -397.9% 14.0% ORLY
Operating Income -2.20B 1.83B ORLY
ROE -31.4% -71.9% MRNA
ROA -19.4% 7.6% ORLY
Total Assets 10.96B 17.39B ORLY
Cash 1.72B 262.18M MRNA
Debt/Equity 0.09 -3.82 ORLY
Current Ratio 2.29 0.75 MRNA
Free Cash Flow -1.25B 1.49B ORLY

Relative Price Performance (Last 90 Days)

MRNA 1M: +126.1% · 3M: +190.0% ORLY 1M: -6.8% · 3M: -4.8%

Current Technical Phase

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (50.4% over 20 days), RSI 61

RSI (14): 61.3 · Price: $143.97

ORLY

Markdown
Sell / avoid

Price below a falling SMA50 (slope -0.3%), weak momentum, RSI 39

RSI (14): 39.0 · Price: $85.82

Fundamentals Snapshot

Metric MRNA ORLY
Market Cap
Forward P/E -29.2 23.5
Trailing P/E 27.3
Revenue (TTM)
Revenue Growth 0.0% 0.1%
Gross Margin -0.7% 0.5%
Operating Margin -5.6% 0.2%
EPS -8.03 3.13
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, ORLY is currently the stronger investment candidate, winning 8 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.